Midatech Pharma (NASDAQ:MTP) news for Monday includes positive results from a Phase I study boosting MTP stock higher.
The goal of this study was to determine the dosage regimen of MTX110 in patients with Diffuse Intrinsic Pontine Glioma (DIPG). This is in preparation for a Phase II study to determine the safety and efficiency of the treatment.
The results from the Phase I study have Midatech Pharma determining a dosage of 60μM and 90μM of MTX110. The dosage will be determined depending on each patient’s reaction after 12 infusions.
The Midatech Pharma news release notes that one of the primary endpoints including patient survival at 12 months. 19 patients will be included in the Phase II study. The Phase I study had seven patients, five of whom lived to 12 months and three of whom are still alive.
It’s worth noting that DIPG is a primary brain tumor mostly found in children. It can’t be removed by surgery and the median survival rate is 10 months with overall survival sitting at 35%. This is based on data from 316 cases.
Sabine Mueller MD PhD, Principal Investigator of the University of California, San Francisco study, said the following.
“DIPG is a devastating pediatric brain cancer with limited treatment options and very poor outcomes. The overall survival data from this Phase I study are encouraging, although further study of MTX110 in DIPG is required to establish whether it can make a difference to these patients and their families.”
MTP stock was up 9.5% as of Monday morning.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article.
